新芝生物
(430685)
| 流通市值：7.75亿 | | | 总市值：12.98亿 |
| 流通股本：5464.25万 | | | 总股本：9151.60万 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 108,698,472.95 | 66,875,602.43 | 27,428,266.45 | 190,794,145.37 |
| 营业收入 | 108,698,472.95 | 66,875,602.43 | 27,428,266.45 | 190,794,145.37 |
| 二、营业总成本 | 90,655,525.72 | 57,827,984.45 | 25,910,739.5 | 138,960,711.37 |
| 营业成本 | 40,868,995.03 | 25,317,549.2 | 10,310,916.27 | 66,409,465 |
| 税金及附加 | 1,138,768.81 | 656,119.26 | 316,569.48 | 2,507,643.76 |
| 销售费用 | 16,923,633.69 | 10,807,721.94 | 5,301,395.54 | 27,217,733.24 |
| 管理费用 | 19,064,108.49 | 12,552,523.48 | 5,717,524.24 | 27,619,441.23 |
| 研发费用 | 14,030,100.63 | 9,456,285.55 | 4,782,985.43 | 18,416,864.42 |
| 财务费用 | -1,370,080.93 | -962,214.98 | -518,651.46 | -3,210,436.28 |
| 其中:利息费用 | 148,495.44 | 108,584.99 | 60,008.91 | 334,005.19 |
| 其中:利息收入 | 1,492,288.54 | 1,039,144.55 | 550,592.14 | 3,538,364.83 |
| 加:公允价值变动收益 | 2,266,077.09 | 1,514,284.48 | 831,441.11 | 2,959,078.69 |
| 加:投资收益 | 2,121,489.2 | 1,729,814.67 | 711,675.67 | 2,973,683.55 |
| 资产处置收益 | 23,875.22 | 23,875.22 | 23,875.22 | 24,377.27 |
| 资产减值损失(新) | -1,304,297.58 | -674,725.81 | -328,796.15 | -2,327,580.27 |
| 信用减值损失(新) | -377,004.2 | 67,843.71 | 100,290.91 | 13,701.73 |
| 其他收益 | 5,262,788.33 | 3,147,674.95 | 1,144,755.98 | 9,822,821.41 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 26,035,875.29 | 14,856,385.2 | 4,000,769.69 | 65,299,516.38 |
| 加:营业外收入 | 1,009,706.17 | 1,006,844.77 | 1,154.45 | 12,031,958.69 |
| 减:营业外支出 | 196,966.36 | 157,494.11 | 260,274.34 | 851,346.78 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 26,848,615.1 | 15,705,735.86 | 3,741,649.8 | 76,480,128.29 |
| 减:所得税费用 | 2,752,158.94 | 1,211,022.64 | 609,562.24 | 9,563,259.33 |
| 六、净利润 | 24,096,456.16 | 14,494,713.22 | 3,132,087.56 | 66,916,868.96 |
| 持续经营净利润 | 24,096,456.16 | 14,494,713.22 | 3,132,087.56 | 66,916,868.96 |
| 归属于母公司股东的净利润 | 21,653,091.07 | 13,060,822.08 | 2,935,721.18 | 58,204,991 |
| 少数股东损益 | 2,443,365.09 | 1,433,891.14 | 196,366.38 | 8,711,877.96 |
| (一)基本每股收益 | 0.24 | 0.15 | 0.03 | 0.64 |
| (二)稀释每股收益 | 0.24 | 0.15 | 0.03 | 0.64 |
| 九、综合收益总额 | 24,096,456.16 | 14,494,713.22 | 3,132,087.56 | 66,916,868.96 |
| 归属于母公司股东的综合收益总额 | 21,653,091.07 | 13,060,822.08 | 2,935,721.18 | 58,204,991 |
| 归属于少数股东的综合收益总额 | 2,443,365.09 | 1,433,891.14 | 196,366.38 | 8,711,877.96 |
| 公告日期 | 2024-10-29 | 2024-08-27 | 2024-04-26 | 2024-04-22 |
| 审计意见(境内) | | | | 标准无保留意见 |